This site is intended for healthcare professionals

Announcement of termination of global license agreements by Otsuka with Akebia Therapeutics, Inc. for vadadustat to treat renal anemia.

Read time: 1 mins
Published:19th May 2022

Otsuka Pharmaceutical Co., Ltd. announces that it has decided to terminate its global license agreements with Akebia Therapeutics, Inc. for vadadustat under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia).

These licenses were signed in in December 2016 for the U.S. and April 2017 for Europe and other regions.

Otsuka and Akebia had been co-developing vadadustat for renal anemia, however in March this year, Akebia received a Complete Response Letter (CRL) from the FDA. As a result, Otsuka has decided to terminate its co-development of vadadustat and has notified Akebia of the termination of its global license agreements.

Condition: Anaemia and CKD
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights